Abstract:Background: Hyzetimibe is a novel inhibitor of cholesterol that specifically targets the NPC1L1 gene. Significant inter-individual variability suggests the existence of an abundance of poor responders and non-responders. In addition, the current literature is inconsistent and controversial regarding the potential impact of the Niemann-Pick C1-Like 1 (NPC1L1) gene on low-density lipoprotein cholesterol (LDL-C) reduction. In light of these concerns, we performed a high-quality clinical trial to investigate the specific characteristics of NPC1L1 gene variation on LDL-C reduction. Methods: This was a multicenter, randomized, double-blind, placebo-controlled, clinical trial with a factorial design. Qualified patients were randomly assigned to one of six treatments: placebo, hyzetimibe (10 or 20 mg), atorvastatin, and atorvastatin plus hyzetimibe (10 or 20 mg). Fasting blood samples were collected and genotyped, and the concentrations of LDL-C and the targeted drug trough were determined to investigate the association between the NPC1L1 gene expression and the reduction of LDL-C. Results: In total, 727 individuals were initially recruited; of these, 444 were eligible to begin the trial. We identified one SNP (g1679C > G) that exerted significantly different impacts on LDL-C levels. As monotherapy, CC carriers experienced significantly higher reductions in the mean LDL-C (-23.99%) than either the GG (-16.45%, p < 0.01) or GC (-13.02%, p < 0.01) carriers in the hyzetimibe (20 mg) group. In contrast, when co-administered with atorvastatin, GC carriers experienced greater LDL-C reduction than non-GC carriers (-52.23% vs. -45.03%) in the hyzetimibe (20 mg) plus atorvastatin group. Furthermore, the proportions of individuals experiencing a reduction in LDL-C by > 50% increased as the dose of hyzetimibe increased from 16.1% to 65.4%. Conclusion: The g1679C > G SNP in the NPC1L1 gene is critical and exerts a differential impact on the response to hyzetimibe treatment. Heterozygotic patients respond with poor efficacy when treated by monotherapy but show good responses in terms of LDL-C reduction when hyzetimibe was co-administered with atorvastatin. To treat hypercholesterolemia in a precise manner with hyzetimibe, it is necessary to identify genotype patients for the g1679C > G SNP. We also highlight the potential necessity for identifying the appropriate subjects to be treated with ezetimibe.

Study on NPC1L1 Gene -762T>C Polymorphism Associated with Promoter Activity

The NPC1L1 Polymorphism 1679C>G is Associated with Gallstone Disease in Chinese Patients.

Effect of Hepatic NPC1L1 on Cholesterol Gallstone Disease and Its Mechanism

Relationship between CD14 C260T promoter polymorphism and serum C-reactive protein levels in patients with coronary artery disease

Correlation of Niemann-Pick C1-like1 gene polymorphism with coronary artery disease

A Genetic Modifier of Niemann-Pick Disease, Type C1

Molecular Characterization of the NPC1L1 Variants Identified from Cholesterol Low Absorbers

The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial

Association Between SLCO1B1 T521C Polymorphism and Risk of Statin-Induced Myopathy: a Meta-Analysis

Systematic Functional Characterization of Cytochrome P450 2E1 Promoter Variants in the Chinese Han Population.

HNF1α and SREBP2 Are Important Regulators of NPC1L1 in Human Liver

NPC1L1 rs217434 A > G as a Novel Single Nucleotide Polymorphism Related to Dyslipidemia in a Korean Population

Development and Validation of a New Genotype-Phenotype Correlation for Niemann-Pick Disease Type C1

Systematic Functional Study of Cytochrome P450 2d6 Promoter Polymorphisms in the Chinese Han Population

Decreased Activities of Apolipoprotein M Promoter Are Associated with the Susceptibility to Coronary Artery Diseases

Association Between The-786t > C 1polymorphism in the Promoter Region of Endothelial Nitric Oxide Synthase (enos) and Risk of Coronary Artery Disease: A Systematic Review and Meta-Analysis

A Novel CYP7A1 Polymorphism is Associated with the Low-Density Lipoprotein Cholesterol Response to Atorvastatin

Increased NPC1 mRNA in skin fibroblasts from Niemann-Pick disease type C patients.

Relationship Between High HDL-C and Hepatic Lipase Promoter 514C/T Polymorphism

Relationship Between A Novel Polymorphism Of The C5l2 Gene And Coronary Artery Disease

New Cellular Models for Niemann–Pick Type C Disease